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Abstract
Background: The UK Clinical Trial Regulations and Good Clinical Practice guidelines specify that the study sponsor
must ensure clinical trial data are accurately reported, recorded and verified to ensure patient safety and scientific
integrity. The methods that are utilised to assess data quality and the results of any reviews undertaken are rarely
reported in the literature. We have recently undertaken a quality review of trial data submitted to a Clinical
Endpoint Committee for adjudication. The purpose of the review was to identify areas that could be improved for
future clinical trials. The results are reported in this paper.
Methods: Throughout the course of the study, all data queries were logged. Following study close out, queries
were coded and categorised. A descriptive and comparative analysis was conducted to determine the frequency of
occurrence for each category by country of origin.
Results: From 1595 endpoint packages reviewed, 782 queries were generated. No source data queries were
generated for countries with ≤ 25 recruited subjects, but both low recruiting and high recruiting countries had a
high number of queries relating to subject identifiers.
Conclusions: The implementation of some simple measures could help improve data quality and lead to
significant savings.
Background
The integrity of the results from clinical trials of investi-
gational medicinal products (CTIMPs) is dependent on
robust and credible data. Poor quality data may make it
difficult for sponsors and research teams to demonstrate
that they have met their legal and professional responsi-
bilities in research. We have recently undertaken a qual-
ity review of the data submitted for adjudication to the
Clinical Endpoint Committee (CEC) of a large interna-
tional double blind, placebo controlled IIIb randomised
trial. The study recruited 2,776 subjects from 280 cen-
tres in 25 countries [1].
The endpoint adjudication process was co-ordinated
and supported by the Clinical Trials Unit (CTU),
Glasgow Royal Infirmary, Glasgow, UK. The CEC, who
were independent of the study sponsor and blinded to
the treatment allocation, reviewed all causes of death,
strokes and myocardial infarctions identified by the
investigator as potential clinical endpoints; revascularisa-
tions were adjudicated by the study physician. Endpoints
were classified according to definitions in the approved
study protocol with the classification based on data
from the Case Report Form and appropriate source
documents (detailed in Clinical Endpoint Reporting
Guidelines). Full details of the endpoint adjudication
process are described elsewhere (submitted for
publication).
To clarify the data requirements of the CEC and mini-
mise the number of queries likely to occur, the CTU
provided training to the sponsor study teams before trial
start up and during the conduct of the trial. The data
received from the sponsor was reviewed by the CTU
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full review was undertaken. This paper describes the
purpose of the review, the methods used to conduct the
review, and the results of the review. Based on the
results, we offer some recommendations for actions that
could reduce the cost associated with incomplete or
inadequate data sets in a large international randomised
controlled trial.
Methods
Data Tracking
In preparation for the trial start up, a system was
devised for tracking all data received from, and sent to,
the study sponsor endpoint office. CTU study specific
Standard Operating Procedures specified the processes
that were to be followed for the receipt, documentation,
r e v i e w ,f o l l o wu pa n dq u a l i t yc o n t r o lo ft h ed a t ai n
order to ensure that each endpoint package was handled
in accordance with Good Clinical Practice [2]. The pro-
cess permitted all data related queries to be recorded,
monitored, and followed up (Figure 1).
Data Review
Following identification of a potential endpoint by an
investigator, the sponsor endpoint office collated and sent
an endpoint package containing the appropriate Case
Report Form pages and a predetermined set of source
documents to the CTU for adjudication. All documents
received from the study sponsor were reviewed by the
team at Glasgow to ensure they were complete, adequate,
de-identified, legible, and consistent. Queries generated
during the review were submitted to the sponsor as soon
as identified. Those which were unanswered by the next
working day were logged on to a database and the response
date entered as appropriate. The database was collated
monthly; outstanding queries were re-submitted to the
sponsor at monthly or two monthly intervals. Where possi-
ble, data queries were resolved before the endpoint
packages were submitted to the CEC for adjudication.
Following study close out, a review of all data queries
g e n e r a t e db yt h eC T Ut e a mo v e rt h ec o u r s eo ft h e
study was undertaken. The purpose of the close out
review was to identify whether there were any recurring
issues that impacted on the quality of the data received
for adjudication, or on the adjudication decision. The
primary objectives of the review were to:
￿ Identify data quality issues
￿ Determine whether the issues were country specific
￿ Determine whether any data queries delayed
adjudication
￿ Identify processes that might improve data quality
and the efficiency of the adjudication process in
future clinical trials.
Data Preparation and Analysis
All identified and logged data queries were entered on
to the CTU study database in text format. These were
then categorised by type and coded numerically. A
descriptive analysis was conducted to identify the num-
ber of queries overall and the frequency with which
each category occurred. A comparative analysis by coun-
try of origin was then conducted to determine whether
there were any significant between-country differences.
The results are discussed below.
Results
Number and Frequency of Queries Generated
Over the course of the study, the CEC reviewed 1595
endpoint packages. Packages could contain information
for more than one endpoint event. From these, 782 data
queries were generated; 164 (21%) of which were re-sub-
mitted to the sponsor on more than one occasion. Most
packages generated only one query (n = 617); 165 gen-
erated more than one. The time between the query
being submitted to the sponsor and being resolved ran-
ged from one day to 22.8 weeks (Mean days = 51.9, SD
88.3; Median 23, IQR, 1.61).
Categories of Queries Generated
For the purpose of identifying whether there were any
consistent or recurring issues, queries were initially
grouped into seven main categories as shown in Table 1.
Figures for data that were received without being de-
identified were not collected from the start of the trial
and are therefore not included.
As illustrated, one half of the queries (51%, n = 401)
related to inconsistent, erroneous or missing dates, miss-
ing signatures, illegible data or errors in unique subject
identifiers (which enable data linkage while ensuring sub-
ject anonymity). Forty three percent (n = 331) related to
missing source data, specified in the protocol and Clinical
Endpoint Reporting Guidelines as necessary for adjudica-
tion. Some of the queries were generated in response to
clinical statements in the so u r c ed a t at h a ts u g g e s t e da
clinical event had occurred, or an investigation had been
performed, but no associated result or report was
included in the endpoint package. The remainder related
to 50 requests from the CEC for additional clinical infor-
mation after its initial review of the endpoint package.
The former resulted in the adjudication decision being
deferred on 39 occasions.
Comparison of Type of Query by Country of Origin
Data were further combined to five categories to enable a
statistical comparison to be made. An overall comparison
of the number and type of data queries across participat-
ing countries suggested that at least one country was sta-
tistically significantly different from the others (P <
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adjusted for ties). Subsequent pairwise comparisons
revealed a number of between-country differences (P <
0.001). In most cases the wide confidence interval (CI)
indicated a non significant result (CI crossed zero). Thus,
there was no clear indication that one country differed
from all others. The proportion of queries in each cate-
gory differed within and across the participating coun-
tries (Table 2). For example, queries relating to unique
subject identifiers were encountered most frequently in
Endpoint package collated 
and added to sponsor 
electronic system 
Accessed and printed by 
CTU team 
Details added to CTU 
tracking spreadsheet
Review of endpoint 
package including source 
documents and ECGs
Package complete  Package incomplete 
Additional source 
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Additional source 
documents received 
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Review of endpoint 
package by CEC 
Endpoint adjudicated  Further information 
required 
Completed 
adjudication form 
couriered to Data 
Management
CTU tracking 
spreadsheet 
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Adjudicated endpoint 
package filed 
Marked as 
completed in 
sponsor electronic 
system 
Figure 1 Clinical Trials Unit Endpoint Review Process.
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Page 3 of 6data from Italy and were the most problematic issue for
Italy. Conversely, queries relating to dates or signatures
were infrequent in Italy compared to most other coun-
tries including Iceland, a country with one of the lowest
reported endpoint events.
The exception to this was Switzerland which had no
date or signature queries but the highest proportion of
source document queries (83%). This was followed by
G r e e c e ,A u s t r i a ,H u n g a r y ,C a n a d aa n dF i n l a n dw h e r e
more than 50% of the queries related to source data.
Reasons for Delayed Response to Queries
A full review of the data was conducted to determine
whether there was a consistent explanation for delays of
more than 90 days. The reason for the delay was not
reported in many cases. Where the data were available, the
delay was identified as being due to events that had not
been anticipated at the study planning stage. These included:
￿ Difficulty in accessing source data relating to a
clinical event where the trial subject was admitted to
a non-participating hospital.
￿ The requirement for the CEC to have access to
both original language and translated documents
from each participating country.
Table 1 Number and percentage of queries generated (all
queries)
Type of query Frequency Relative %
Unique Subject Identifiers
1 115 14.7
Missing baseline or event ECGs 117 15.0
Missing Troponin
2/cardiac enzymes 83 10.6
Missing results/reports
3 131 16.8
Illegible or obscured data 105 13.4
Dates/signatures
4 181 23.1
Additional information
5 50 6.4
Total 782 100
Erroneous or inconsistent
1; level, type, or lower limit of detection
2;
neurological or cardiac imaging
3; erroneous, missing, or inconsistent dates;
missing signatures
4; insufficient clinical information to permit adjudication
5.
Table 2 Type and proportion of queries generated from data received from participating countries
Type of
query
Unique subject
identifiers
Source Documents (Results/
reports)
Clarification/
legibility
Dates/
Signatures
Additional clinical
Information
Country (Relative %) (Relative %) (Relative %) (Relative %) (Relative %)
Australia 20.5 48.7 15.4 10.3 5.1
Austria 10.8 56.7 10.8 21.6 0
Belgium 0 33.3 20.8 33.3 12.5
Canada 7.1 54.8 14.3 21.4 2.4
Czech
Rebublic
10.7 50.0 17.9 14.3 7.1
Denmark 9.7 35.5 6.4 41.9 6.4
Finland 22.2 51.8 14.8 7.4 3.7
France 10.3 48.3 13.8 17.2 10.3
Germany 14.0 35.1 10.5 31.6 8.8
Hungary 12.3 56.1 10.5 19.3 1.7
Iceland 0 0 0 100 0
Netherlands 10.5 38.6 15.8 24.6 10.5
Norway 11.1 44.4 11.1 22.2 11.1
Poland 11.4 50.0 11.4 16.0 11.4
Sweden 15.4 53.8 15.4 11.5 3.8
Switzerland 16.7 83.3 0 0 0
UK/Ireland 17.5 37.5 6.2 30.0 8.7
Brazil 15.3 25.0 23.6 29.2 6.9
Bulgaria 33.3 29.2 12.5 25.0 0
Greece 0 100 0 0 0
Italy 40.0 33.3 13.3 6.7 6.7
Korea 30.8 30.8 7.7 30.7 0
Mexico 25.0 16.7 25.0 29.2 4.2
Turkey 0 33.3 0 66.7 0
Total 14.4 43.6 11.6 25.4 5.1
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reviewer that had not been identified or reported by
the sponsor study team.
￿ Delay in query response time due to transfer of
study management responsibility (and outstanding
queries) from one team and/or country to another
while the study was in progress.
Discussion
ICH GCP Guidelines [2] specify that clinical trial data
must be accurately reported, recorded, and verified to
ensure its scientific integrity. Our review revealed a
number of data errors and inconsistencies that occurred
repeatedly, despite being highlighted to the sponsor at
an early stage and at intervals during the study.
Although the delay in the resolution of queries had no
impact on the trial results, it did have an impact on
timelines and was resource intensive for the sponsor as
well as the CTU team. Some of the delays were due to
issues that had not been anticipated at the study plan-
ning stage and, hence, could not have been avoided.
They do, however, highlight the need to give some con-
sideration to their potential impact when planning
future studies.
It is possible that some of the delays incurred were
due to sub optimal staffing levels, high staff turnover,
particularly as the study neared completion, or different
work practices (such as vacation times) in some coun-
tries. It is also possible that some of the between coun-
try differences were due to the national characteristics
of individual health care systems. In some cases, the
geographical spread of study sites or low resource
investment may have been problematic for monitors
when arranging site visits to check source data or obtain
required information. The qualifications or professional
background of the monitor may also be influential.
Some countries employ clinically qualified staff in moni-
toring roles whereas others do not; this may have a
positive or negative impact on the data collected.
A well planned prospective study would be required to
identify any statistically significant and more subtle dif-
ferences between sites/and or countries and the cost
implications of addressing these.
A small number of data errors at one site may not
have a negative impact on the conduct of a trial or data
integrity. However, when the problem occurs over a
number of sites the cumulative effect may be great and
the financial impact extensive. It is imperative that these
issues are addressed.
It is important to note that the data quality issues dis-
cussed in this report were identified at a late stage in
the data collection and review process, that is, when the
endpoint packages were submitted for adjudication. At
that point, the data had been exposed to a series of
monitoring procedures and data checks. As the results
do not include figures for data queries that were
resolved quickly (within one working day), or data that
was not de-identified before being sent for adjudication,
the extent of the problem is underestimated. Moreover,
transferring identifiable patient data from clinical sites
to the sponsor or clinical research organisations
breaches the Principles of Good Clinical Practice [2]
and the data protection legislation in the UK [3] and
elsewhere. These are issues that clearly need to be
addressed. Based on the results of our analysis we,
therefore, make the following recommendations:
￿ In addition to Good Clinical Practice training, all
members of the clinical research team should be
trained in the requirements of the trial before study
start up. This would ensure that all staff are aware
of their trial specific responsibilities and data report-
ing requirements.
￿ New members of the research team should be
trained in the content of the study protocol and
study specific documentation requirements of the
trial before they are required to collect, handle, or
review data. This would minimise the risk to data
quality, particularly where there may be a high turn-
over of research support staff.
￿ Providing those who are new to research with a
mentor until they are competent to fulfil their role is
likely to be an effective way to reduce cost and drive
up the quality of the data.
￿ Study specific endpoint data and documentation
requirements should be accessible to trial staff at all
times. This would provide a reference point for any
queries that might arise and thus circumvent poten-
tial errors.
￿ A system should be put in place which permits
changes to study requirements to be disseminated to
all trial staff in a timely and effective manner. This
would ensure that all trial staff are kept informed of
current documentation processes and procedures. A
system that alerts trial staff to any required amend-
ments, or protocol changes, and associated data
requirements, and acknowledges receipt of these,
would be advantageous.
￿ Where possible, an electronic rather than paper
based CRF should be used. This would reduce the
potential for errors by preventing the submission of
incomplete data, or data that exceeds pre-determined
parameters, and reduce the need for double entry.
￿ When the source documents required to support a
study endpoint are being agreed, consideration
should be given to how accessible the required docu-
ments will be to trial staff.
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early stage in the trial set up would identify any
recurrent queries and allow these to be addressed.
Conclusions
The results of this analysis highlight the need to imple-
ment measures that will reduce the problems associated
with the collection of data required to support the end-
point adjudication process in large multicentre trials. Ade-
quate and appropriate training of all staff involved in the
process before study start up and throughout its duration
will eliminate many of the minor problems identified. A
simple data tracking system established at an early stage in
the trial set up would identify any recurrent queries and
allow these to be addressed. As data sent for review and
adjudication without being adequately de-identified were
not logged from the date of study start up, the results may
underestimate the full extent of the problem.
Whether our recommendations will save time or
money is likely to depend on the nature of the study,
what is implemented and how it is implemented. The
resources spent on the implementation of any of these
recommendations would need to be justified. A complex
trial may require more training resources. However,
ensuring that submitted documents contain all the
required signatures and dates could resolve some of the
issues relatively easily and cost effectively. For all stu-
dies, any reduction in the time and effort spent retriev-
ing missing or incomplete clinical trial data should
result in cost savings.
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